Sorafenib Tablets

Solicitation / RFP / RFQ

This document is a Solicitation/Contract/Order for Commercial Items, specifically Solicitation Number SPE2D2-25-R-0016, with an award/effective date of 2026 MAY 28 and an order number of SPE2D2-26-D-0016. The total award amount is listed as $10,256,568.00.

The "Schedule of Supplies/Services" is referenced as "See Schedule" and "See Addendum," indicating that detailed requirements and deliverables are provided in separate attached documents or sections.

• Contract Type: Commercial Item

• Period of Performance: Award/Effective Date is 2026 MAY 28.

• Estimated Value: $10,256,568.00

• Offer Due Date: Not explicitly stated on this page, but the solicitation issue date is 2025 JUN 04.

• Evaluation criteria are not detailed on this page.

The acquisition is marked as "UNRESTRICTED OR SET ASIDE," with options for Small Business, HUBZone Small Business, Service-Disabled Veteran-Owned Small Business, and Women-Owned Small Business (WOSB) eligible under the WOSB Program. The NAICS code is 325412 with a size standard of 1,500 employees.

• The solicitation incorporates by reference FAR 52.212-1, 52.212-4, and 52.212-3. FAR 52.212-5 is also attached.
• An attachment named "Award Document - Sorafenib SPE2D2-26-D-0016 Signed.pdf" is listed.

Solicitation / RFP / RFQ

This document is a solicitation (SPE2D2-25-R-0016) for Sorafenib 200 MG Tablets (NDC 50419-0489-01), a 120-count bottle. It is part of a larger contract (SPE2D2-26-D-0010) with an estimated total award amount of $10,256,568.00 over 5 years.

• Product: Sorafenib 200 MG Tablets, 120 count bottle.

• Quantity: Estimated quantities are provided for a Base Year and four Option Years, with a total estimated quantity of 2100 bottles over 5 years.

• Manufacturer/Distributor: Bayer HealthCare Pharmaceuticals Inc. is listed as the contractor, with manufacturing and packaging facilities located in Leverkusen, Germany.

• Contract Number: SPE2D2-26-D-0010

• Estimated Total Award Amount: $10,256,568.00

• Period of Performance: Base Year plus 4 Option Years (5 years total).

• Contract Type: The document indicates it is a solicitation that resulted in an award. Bayer Healthcare's offer was determined to be the lowest price technically acceptable.

• Solicitation Number: SPE2D2-25-R-0016

• Original Offer Date: July 28, 2025

• Amendments: The solicitation was amended twice, extending the submission deadline to August 4, 2025.

• Final Proposal Revisions: Opened on March 24, 2026. Bayer Healthcare did not revise pricing from their initial offer.

• The acquisition is marked as "UNRESTRICTED."

• The document incorporates numerous Federal Acquisition Regulation (FAR) and Defense Federal Acquisition Regulation Supplement (DFARS) clauses by reference.

• Appendix A lists current Pharmaceutical Prime Vendors as of the solicitation date.